Forbes August 13, 2019
This is an exciting summer for the Digital Therapy (DTX) industry. Recently Voluntis announced marketing authorizationof the first oncology disease management software platform. This comes on the heels of two impressive IPOs for digital health companies Livongo and Health Catalyst. Livingo achieved a valuation of over $3 billion on its first day, and Health Catalyst was over $1 billion. This is welcome news since venture capitalists have invested billions into DTX but have been waiting for liquidity in public markets. Voluntis was one of the first in this category to go public on Euronext Paris in 2018.
The Voluntis announcement is being called the first digital therapeutic broadly applicable to oncology. Chief Executive Officer Pierre Leurent said, “this provides market...
Today's Sponsors
Today's Sponsor